Merck’s vicriviroc for metastatic microsatellite stable colorectal cancer (CRC) saw its Phase Transition Success Rate (PTSR) launch 10 points to 42% after its Phase II trial completed. The PTSR score change occurred on 21 June after ClinicalTrials.gov updated the trial from active to completed on 17 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

As to its primary endpoints, the 42-patient Phase II (NCT03631407) measured objective response rate, dose-limiting toxicities and adverse events for two doses of vicriviroc, each in combination with Merck’s Keytruda (pembrolizumab), according to ClinicalTrials.gov. Vicriviroc is a C-C Motif chemokine receptor 5 (CCR5) antagonist, which acts against HIV.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase II update also resulted in a four-point bump to the drug’s Likelihood of Approval (LoA), which rose to 17%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm and is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

Merck has a market cap of $192.92bn.